铁与口服活性促排药物L1（3-羟基-1,2-二甲基-4-吡啶酮）的络合作用

Complexation of iron with the orally active decorporation drug L1 (3-hydroxy-1,2-dimethyl-4-pyridinone).

作者信息

Kline M A, Orvig C

机构信息

Department of Chemistry, University of British Columbia, Vancouver, Canada.

出版信息

Clin Chem. 1992 Apr;38(4):562-5.

PMID:1568323

Abstract

The stability constants for the Fe(III) complexes of the orally active iron decorporation drug L1 (3-hydroxy-1,2-dimethyl-4-pyridinone) have been determined by potentiometric titration [glass electrode, 25.0 degrees C, mu = 0.15 mol/L (isotonic) NaCl]. A simple computer model of blood plasma (citrate 100 mumol/L, transferrin 37 mumol/L) has been used to compare the Fe(III) binding efficacies in blood of L1 and the clinically used intravenously administered chelating agent deferoxamine.

摘要

通过电位滴定法[玻璃电极，25.0℃，μ = 0.15 mol/L（等渗）NaCl]测定了口服活性铁促排药物L1（3-羟基-1,2-二甲基-4-吡啶酮）的铁（III）配合物的稳定常数。利用一个简单的血浆模型（柠檬酸盐100 μmol/L，转铁蛋白37 μmol/L）比较了L1和临床使用的静脉注射螯合剂去铁胺在血液中与铁（III）的结合效率。